AF
JBIO

Amalgamated Financial’s Jade Biosciences JBIO Stock Holding History

Amalgamated Financial’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$27K Buy
+42
New +$16.3K ﹤0.01% 2649

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

Amalgamated Financial's JBIO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Jade Biosciences (JBIO) in Q1 2022: 42 shares worth $27K. The stake represents ﹤0.01% of the portfolio and ranks #2649 among its holdings.

45 funds tracked by Wall St. Rank hold JBIO as of Q1 2022.

  • Amalgamated Financial held 42 shares of Jade Biosciences worth $27K as of Q1 2022.
  • Jade Biosciences was a new Amalgamated Financial position in Q1 2022.
  • Jade Biosciences made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2649 holding.
  • 45 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.